Cardiovascular Interventions and Kidney Disease

2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices

Cardiometabolic Health Congress

JULY 17, 2024

February 2024 FDA Approvals: Innovations in Cardiovascular Interventions XACT Carotid Stent System (Approved: 02/07/2024) This approval expands the indications to be used during a Transcarotid Artery Revascularization (TCAR) procedure to prevent future strokes. The label includes a “black box” warning for CV risk due to blood clots.

Tricuspid

Tricuspid Open-Heart Surgery Kidney Disease Pediatrics

Predictors of worse outcome after postponing non-emergency cardiac interventions during the COVID-19 pandemic

Open Heart

JULY 17, 2023

Objective Deferral of non-emergency cardiac procedures is associated with increased early emergency cardiovascular hospitalisation. This study aimed to identify predictors of worse clinical outcome after deferral of non-emergency cardiovascular interventions. to 5.12; p=0.049), chronic kidney disease (HR 1.89; 95% CI 1.03

COVID-19

COVID-19 Outcomes Cardiovascular Interventions Risk Factors

Cardiovascular Update

Ultra-Low Contrast IVUS-Guided PCI in Patients With Severe Chronic Kidney Disease: An Observational Prospective Study

2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices

Predictors of worse outcome after postponing non-emergency cardiac interventions during the COVID-19 pandemic

Webinars

Stay Connected